Intra-Cellular Therapies, Inc.
(NASDAQ : ITCI)

( )
ITCI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.56%297.201.4%$596.31m
AMGNAmgen, Inc.
0.44%233.841.3%$498.51m
GILDGilead Sciences, Inc.
0.22%67.081.0%$356.60m
REGNRegeneron Pharmaceuticals, Inc.
0.56%367.672.6%$292.07m
VRTXVertex Pharmaceuticals, Inc.
0.41%220.271.9%$272.17m
ILMNIllumina, Inc.
0.11%326.943.5%$235.54m
CLVSClovis Oncology, Inc.
12.98%12.1014.7%$219.20m
ARWRArrowhead Pharmaceuticals, Inc.
4.56%70.8611.5%$213.63m
ALXNAlexion Pharmaceuticals, Inc.
-1.14%111.202.0%$196.66m
EXASEXACT Sciences Corp.
1.32%85.3024.0%$166.59m
AAgilent Technologies, Inc.
1.61%82.931.6%$155.82m
GBTGlobal Blood Therapeutics, Inc.
1.12%75.956.0%$134.81m
SRPTSarepta Therapeutics, Inc.
0.40%106.1714.6%$133.20m
BOLDAudentes Therapeutics, Inc.
0.32%59.511.4%$132.22m
BLUEbluebird bio, Inc.
11.87%85.6914.2%$130.86m

Company Profile

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.